Supplemental Table S1. Summary of safety findings from REFLECTIONS B328-06study [2]. (© The Author(s) 2019. https://creativecommons.org/licenses/by-nc/4.0/)

|  |  |  |
| --- | --- | --- |
| **Category** | **RTX-PFa**  **(N = 196)** | **RTX-EUa**  ***(*N= 197)** |
| TEAEs, all-causality, n (%) | | |
| Subjects with AEs | 156 (79.6) | 145 (73.6) |
| SAEs | 17 (8.7) | 15 (7.6) |
| Grade ≥3 AEsb | 28 (14.3) | 26 (13.2) |
| AEs leading to infusion interruptionc | 37 (18.9) | 51 (25.9) |
| TEAEs by preferred term, all-causality, n (%)d | | |
| Infusion-related reaction | 49 (25.0) | 59 (29.9) |
| Nausea | 15 (7.7) | 17 (8.6) |
| Diarrhea | 14 (7.1) | 12 (6.1) |
| Throat irritation | 14 (7.1) | 10 (5.1) |
| Cough | 11 (5.6) | 11 (5.6) |
| Oropharyngeal pain | 2 (1.0) | 10 (5.1) |
| Fatigue | 12 (6.1) | 13 (6.6) |
| Asthenia | 9 (4.6) | 13 (6.6) |
| Pyrexia | 12 (6.1) | 11 (5.6) |
| Pruritus | 13 (6.6) | 22 (11.2) |
| Rash | 10 (5.1) | 8 (4.1) |
| Back pain | 8 (4.1) | 10 (5.1) |
| Headache | 16 (8.2) | 19 (9.6) |
| TEAEs, treatment-related, n (%) |  |  |
| Subjects with AEs | 86 (43.9) | 94 (47.7) |
| SAEs | 2 (1.0) | 2 (1.0) |
| Grade ≥3 AEs | 9 (4.6) | 8 (4.1) |
| AEs leading to temporary treatment discontinuation | 34 (17.3) | 50 (25.4) |

aSafety population.

bIncludes 1 (0.5%) death in each treatment group, due to disease progression.

cSubjects who had AEs leading to a temporary treatment interruption.

d≥5% of subjects in either treatment group.

AE: adverse event; SAE: serious adverse event; RTX-EU: rituximab reference product (MabThera®) sourced from the European Union; RTX-PF: PF-05280586; TEAE: treatment-emergent adverse event.

**References**

1. Cohen S, Emery P, Greenwald M *et al*. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis*.* *Br. J. Clin. Pharmacol.* 82(1), 129-138 (2016).

2. Sharman JP, Liberati AM, Ishizawa K *et al*. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL)*.* *Biodrugs* 34(2), 171-181 (2020).